Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
1 min read
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing body weight.
Novo Nordisk’s share price fell 8%.
Novo Nordisk said CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly’s tirzepatide in the trial.
For the latest news, follow us on Twitter @Aaj_Urdu. We are also on Facebook, Instagram and YouTube.
